Ganosporeric acid ACAS# 135357-25-4 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 135357-25-4 | SDF | Download SDF |
PubChem ID | 131872.0 | Appearance | Powder |
Formula | C30H38O8 | M.Wt | 526.63 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (2R,6R)-2-methyl-4-oxo-6-[(10S,13R,14R,17R)-4,4,10,13,14-pentamethyl-3,7,11,12,15-pentaoxo-1,2,5,6,16,17-hexahydrocyclopenta[a]phenanthren-17-yl]heptanoic acid | ||
SMILES | CC(CC(=O)CC(C)C(=O)O)C1CC(=O)C2(C1(C(=O)C(=O)C3=C2C(=O)CC4C3(CCC(=O)C4(C)C)C)C)C | ||
Standard InChIKey | AKWNYHCILPEENZ-GESKOEBASA-N | ||
Standard InChI | InChI=1S/C30H38O8/c1-14(10-16(31)11-15(2)26(37)38)17-12-21(34)30(7)22-18(32)13-19-27(3,4)20(33)8-9-28(19,5)23(22)24(35)25(36)29(17,30)6/h14-15,17,19H,8-13H2,1-7H3,(H,37,38)/t14-,15-,17-,19?,28+,29+,30+/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Ganosporeric acid A Dilution Calculator
Ganosporeric acid A Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.8989 mL | 9.4943 mL | 18.9887 mL | 37.9773 mL | 47.4717 mL |
5 mM | 0.3798 mL | 1.8989 mL | 3.7977 mL | 7.5955 mL | 9.4943 mL |
10 mM | 0.1899 mL | 0.9494 mL | 1.8989 mL | 3.7977 mL | 4.7472 mL |
50 mM | 0.038 mL | 0.1899 mL | 0.3798 mL | 0.7595 mL | 0.9494 mL |
100 mM | 0.019 mL | 0.0949 mL | 0.1899 mL | 0.3798 mL | 0.4747 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Avenanthramide A
Catalog No.:BCX1136
CAS No.:108605-70-5
- Avenanthramide B
Catalog No.:BCX1135
CAS No.:108605-69-2
- 3-Feruloyl-4-caffeoylquinic acid
Catalog No.:BCX1134
CAS No.:96990-65-7
- β-Sitosteryl acetate
Catalog No.:BCX1133
CAS No.:915-05-9
- Tetraacetylphytosphingosine
Catalog No.:BCX1132
CAS No.:13018-48-9
- L-Guluronic Acid Sodium Salt
Catalog No.:BCX1131
CAS No.:15769-56-9
- Ostruthine
Catalog No.:BCX1130
CAS No.:148-83-4
- Agigenin
Catalog No.:BCX1129
CAS No.:55332-76-8
- Salidroside pentaacetate
Catalog No.:BCX1128
CAS No.:39032-08-1
- 2,3,4,6-tetraacetate Salidroside
Catalog No.:BCX1127
CAS No.:28251-63-0
- (-)-Epitaxifolin
Catalog No.:BCX1126
CAS No.:114761-89-6
- Zymosterol
Catalog No.:BCX1125
CAS No.:128-33-6
- N-methyltyramine
Catalog No.:BCX1138
CAS No.:370-98-9
- 3α-Hydroxymogrol
Catalog No.:BCX1139
CAS No.:1343402-73-2
- Ligustrosidic acid
Catalog No.:BCX1140
CAS No.:96382-89-7
- Presenegenin
Catalog No.:BCX1141
CAS No.:2163-40-8
- Hydroxypropyl tetrahydropyrantriol
Catalog No.:BCX1142
CAS No.:439685-79-7
- Euphornin
Catalog No.:BCX1143
CAS No.:80454-47-3
- Reptoside
Catalog No.:BCX1144
CAS No.:53839-03-5
- Jaligonic acid
Catalog No.:BCX1145
CAS No.:51776-39-7
- 24(28)-Dehydroergosterol
Catalog No.:BCX1146
CAS No.:29560-24-5
- Eicosapentaenoic acid
Catalog No.:BCX1147
CAS No.:10417-94-4
- Toralactone
Catalog No.:BCX1148
CAS No.:41743-74-2
- Rubropunctatin
Catalog No.:BCX1149
CAS No.:514-67-0
Circular RNA NF1-419 Inhibits Proliferation and Induces Apoptosis by Regulating Lipid Metabolism in Astroglioma Cells.[Pubmed:34376137]
Recent Pat Anticancer Drug Discov. 2022;17(2):162-177.
BACKGROUND: Astroglioma is the most common primary tumor of the central nervous system. Currently, there is no effective treatment for astroglioma. In the present study, the extract (L3) from Ganoderma Lucidum (G. lucidum) was found to inhibit the growth of astroglioma U87 cells and change the expression of circular RNAs (circRNAs). One of these, including the circular NF1-419 (circNF1-419), was of interest because NF1 gene is a classic tumor suppressor gene. OBJECTIVES: The functional role of circ-NF1-419 in the inhibition of astroglioma cells remains unknown. This study focuses on the role of circNF1-419 in functional abnormalities of U87 astroglioma cells and aims to elaborate on its regulatory mechanism. METHODS: The circNF1-419 overexpressing U87 (U87-NF1-419) cells were constructed. We generated U87-NF1-419 to evaluate the role of circNF1-419 on cell cycle, apoptosis, proliferation, tumor growth and metabolic regulation. Finally, we used docking screening to identify compounds in G. lucidum extracts that target circ-419. RESULTS: U87-NF1-419 can promote cell apoptosis and regulate lipid metabolism through glycerophospholipid metabolism and retrograde endocannabinoid signaling. Further examinations revealed that the expression of metabolic regulators, such as L-type voltage-operated calcium channels (L-VOCC), phospholipase C-beta3 (PLCbeta3), Mucin1, cationic amino acid transporter 4 (CAT4), cationic amino acid transporter 1 (CAT1) and a kinase (PRKA) anchor protein 4 (AKAP4) was inhibited, while phosphatidylserine synthase 1 (PTDSS1) was enhanced in U87-NF1-419 cells. In vivo experiments showed that circNF1-419 inhibits tumor growth in BALB/C nude mice, and enhanced AKAP4 and PTDSS1 in tumor tissues. The virtual docking screening results supported that Ganosporeric acid A, ganodermatriol, ganoderic acid B and alpha-D-Arabinofuranosyladenine in L3 could activate circNF1-419 in astroglioma treatment. CONCLUSION: This study indicated that circNF1-419 could be a therapeutic target for the clinical treatment of astroglioma. L3 from Ganoderma Lucidum (G. lucidum) could inhibit astroglioma growth by activating circNF1-419.
Discovery of Ganoderma lucidum triterpenoids as potential inhibitors against Dengue virus NS2B-NS3 protease.[Pubmed:31836806]
Sci Rep. 2019 Dec 13;9(1):19059.
Dengue virus (DENV) infection causes serious health problems in humans for which no drug is currently available. Recently, DENV NS2B-NS3 protease has been proposed as a primary target for anti-dengue drug discovery due to its important role in new virus particle formation by conducting DENV polyprotein cleavage. Triterpenoids from the medicinal fungus Ganoderma lucidum have been suggested as pharmacologically bioactive compounds and tested as anti-viral agents against various viral pathogens including human immunodeficiency virus. However, no reports are available concerning the anti-viral activity of triterpenoids from Ganoderma lucidum against DENV. Therefore, we employed a virtual screening approach to predict the functional triterpenoids from Ganoderma lucidum as potential inhibitors of DENV NS2B-NS3 protease, followed by an in vitro assay. From in silico analysis of twenty-two triterpenoids of Ganoderma lucidum, four triterpenoids, viz. Ganodermanontriol (-6.291 kcal/mol), Lucidumol A (-5.993 kcal/mol), Ganoderic acid C2 (-5.948 kcal/mol) and Ganosporeric acid A (-5.983 kcal/mol) were predicted to be viral protease inhibitors by comparison to reference inhibitor 1,8-Dihydroxy-4,5-dinitroanthraquinone (-5.377 kcal/mol). These results were further studied for binding affinity and stability using the molecular mechanics/generalized Born surface area method and Molecular Dynamics simulations, respectively. Also, in vitro viral infection inhibition suggested that Ganodermanontriol is a potent bioactive triterpenoid.
[Studies on the triterpenoid constituents of the spores from Ganoderma lucidum karst].[Pubmed:1957672]
Yao Xue Xue Bao. 1991;26(4):267-73.
Five compounds were isolated from the ether soluble fraction of the spores of Ganoderma lucidum. On the basis of their chemical properties and spectral data (MS, UV, IR, 1H and 13CNMR), they were identified as 3,7,11,12,15,23-hexaoxo-5 alpha-lanosta-8-en-26-oic acid (I), 3 beta,7 beta-dihydroxy-11,15,23-trioxo-5 alpha-lanosta-8-en-26-oic acid (II), 7 beta-hydroxy-3,11,15,23-tetraoxo-5 alpha-lanosta-8-en-26-oic acid (III), 3,7,11,15,23-pentaoxo-5 alpha-lanosta-8-en-26-oic acid (IV), 24,25,26-trihydroxy-5 alpha-lanosta-7,9 (11)-dien-3-one (V), Compound I is a new natural product, named Ganosporeric acid A. Compounds II, III, IV and V were obtained for the first time from the spores of Ganoderma lucidum.